A Clozapine-Responsive GPCR-Based Gene Switch for Pharmacological Control of Gene Expression in Mammalian Cells and In Vivo
International Journal of Molecular Sciences · 09.04.2026 · 27 (8) · 3381
DOI: 10.3390/ijms27083381 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.04.2026. Verfasst von Guanyang Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Hauptthemen laut MEDLINE: Clozapine, Receptors, G-Protein-Coupled, Gene Expression Regulation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Sun Yat-sen University, Research Talents Program of The First Affiliated Hospital of Sun Yat-sen University.
Abstract (Originalsprache)
The safe and precise regulation of therapeutic gene expression remains a major challenge for mammalian synthetic biology and cell-based therapies. Many existing inducible systems rely on non-mammalian regulatory components or ligands with limited clinical compatibility. Designer receptors exclusively activated by designer drugs (DREADDs) offer a human G protein-coupled receptor (GPCR)-based framework for pharmacological control of intracellular signaling, yet their application as clinically relevant gene-regulation platforms remains underexplored. Here, we report a clozapine-responsive gene switch that couples a designer GPCR to signaling-dependent transcriptional control. By linking clozapine-activated receptors to cyclic adenosine monophosphate (cAMP)- or calcium-responsive synthetic promoters, receptor activation is converted into robust transgene expression across a broad dynamic range, with sensitivity to sub-nanomolar to low-nanomolar clozapine concentrations. In vivo, alginate-encapsulated reporter cells implanted in C57BL/6J mice responded to systemic or local clozapine administration with efficient secretion of a reporter protein, achieving robust induction at low daily doses (0.3 mg/kg) following either oral administration or local delivery. Together, these results establish a human GPCR-based clozapine-responsive gene switch that integrates regulation by a clinically used small molecule with modular transcriptional outputs, providing an additional approach for pharmacologically controllable gene expression in mammalian cells and in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
- Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
ORCID-Profile: Peng Bai
Förderung
- Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities, Sun Yat-sen University
- Research Talents Program of The First Affiliated Hospital of Sun Yat-sen University
- Guang-dong Provincial Talent Program
Zitieren
APA
Chen, G., Li, S., & Bai, P. (2026). A Clozapine-Responsive GPCR-Based Gene Switch for Pharmacological Control of Gene Expression in Mammalian Cells and In Vivo. International Journal of Molecular Sciences, 27(8), 3381. https://doi.org/10.3390/ijms27083381
Vancouver
Chen G, Li S, Bai P. A Clozapine-Responsive GPCR-Based Gene Switch for Pharmacological Control of Gene Expression in Mammalian Cells and In Vivo. International Journal of Molecular Sciences. 2026;27(8):3381. doi:10.3390/ijms27083381
BibTeX
@article{Chen2026,
author = {Chen, Guanyang and Li, Shiting and Bai, Peng},
title = {A Clozapine-Responsive GPCR-Based Gene Switch for Pharmacological Control of Gene Expression in Mammalian Cells and In Vivo},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3381},
doi = {10.3390/ijms27083381}
}
EUVIMED